Spire Wealth Management Raises Stake in Exact Sciences Co. (NASDAQ:EXAS)

Spire Wealth Management lifted its holdings in shares of Exact Sciences Co. (NASDAQ:EXASFree Report) by 20.5% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,152 shares of the medical research company’s stock after acquiring an additional 707 shares during the period. Spire Wealth Management’s holdings in Exact Sciences were worth $283,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Vanguard Group Inc. grew its stake in Exact Sciences by 4.4% during the 3rd quarter. Vanguard Group Inc. now owns 16,676,611 shares of the medical research company’s stock worth $541,823,000 after buying an additional 698,740 shares during the last quarter. Capital World Investors grew its stake in shares of Exact Sciences by 2.6% in the 2nd quarter. Capital World Investors now owns 6,797,960 shares of the medical research company’s stock valued at $638,328,000 after purchasing an additional 173,174 shares during the last quarter. Artisan Partners Limited Partnership grew its stake in shares of Exact Sciences by 31.8% in the 2nd quarter. Artisan Partners Limited Partnership now owns 3,542,744 shares of the medical research company’s stock valued at $332,664,000 after purchasing an additional 855,418 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Exact Sciences by 4.1% in the 2nd quarter. Geode Capital Management LLC now owns 2,696,040 shares of the medical research company’s stock valued at $252,753,000 after purchasing an additional 104,983 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its stake in shares of Exact Sciences by 8.7% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,666,008 shares of the medical research company’s stock valued at $113,655,000 after purchasing an additional 133,945 shares during the last quarter. Institutional investors and hedge funds own 89.13% of the company’s stock.

Exact Sciences Stock Performance

NASDAQ EXAS opened at $60.64 on Friday. The company has a quick ratio of 2.13, a current ratio of 2.41 and a debt-to-equity ratio of 0.74. Exact Sciences Co. has a fifty-two week low of $58.43 and a fifty-two week high of $100.77. The stock has a market cap of $10.97 billion, a price-to-earnings ratio of -38.14 and a beta of 1.27. The business has a fifty day moving average of $67.49 and a 200-day moving average of $71.28.

Insider Activity

In other news, insider Brian Baranick sold 879 shares of the stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $73.50, for a total value of $64,606.50. Following the completion of the sale, the insider now owns 7,992 shares in the company, valued at $587,412. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Exact Sciences news, insider Brian Baranick sold 879 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $73.50, for a total transaction of $64,606.50. Following the completion of the sale, the insider now owns 7,992 shares in the company, valued at approximately $587,412. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Sarah Condella sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $73.50, for a total value of $147,000.00. Following the sale, the executive vice president now owns 69,423 shares of the company’s stock, valued at approximately $5,102,590.50. The disclosure for this sale can be found here. Over the last quarter, insiders sold 4,879 shares of company stock worth $351,607. 1.30% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have weighed in on EXAS shares. Piper Sandler lowered their target price on Exact Sciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research note on Monday, October 16th. TheStreet upgraded Exact Sciences from a “d+” rating to a “c-” rating in a research note on Tuesday, January 9th. Benchmark upgraded Exact Sciences from a “hold” rating to a “buy” rating and set a $91.00 price target on the stock in a research note on Tuesday, January 2nd. Guggenheim initiated coverage on Exact Sciences in a research note on Thursday, December 14th. They issued a “buy” rating and a $90.00 price target on the stock. Finally, Wolfe Research initiated coverage on Exact Sciences in a research note on Wednesday, December 13th. They issued an “outperform” rating and a $95.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $97.06.

Check Out Our Latest Stock Report on EXAS

Exact Sciences Company Profile

(Free Report)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.

Featured Articles

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Co. (NASDAQ:EXASFree Report).

Institutional Ownership by Quarter for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.